The purpose of this study was to analyze the outcome of patients with multiple myeloma (MM) responding to initial chemotherapy who received intensification with high-dose therapy/autotransplantation (HDT) as compared to that of those who were continued on standard chemotherapy. From 1 January 1990 to 30 June 1998, 64 patients with MM who were younger than 65 years achieved a response to initial chemotherapy. Due to referral reasons, patients preference or inclusion in trials, 31 patients received HDT as early intensification while 33 were continued on standard chemotherapy. The presenting features were similar in both groups, except for the median age, which was lower in the HDT group (53 vs 58 years, P = 0.007). Complete responsenegative immunofixation -(CR) was achieved in 12 of 31 (39%) patients intensified with HDT and in two of 33 (6%) patients who were continued on conventional chemotherapy (P = 0.002). Event-free survival (EFS) was significantly longer in the HDT group (median, 43 vs 21 months; P = 0.007). Overall survival (OS) was not significantly different between groups (median, 62 vs 38 months; P = 0.21). However, patients in the HDT group who achieved CR had an EFS (median, 51 vs 31 months; P = 0.03) as well as an OS (median, not reached vs 50 months; P = 0.0006) significantly longer than those achieving a lower degree of response. In conclusion, this non-randomized study shows that early HDT increases CR rate and prolongs EFS. In addition, these results highlight CR as a crucial step for achieving long-lasting disease control and prolonged survival in patients with MM. Bone Marrow Transplantation (2000) 26, 845-849. Keywords: multiple myeloma; high-dose therapy; autotransplantation; chemotherapy Treatment of patients with multiple myeloma (MM) by conventional chemotherapy is disappointing with median survival times ranging from 2 to 3 years.
chemotherapy does not result in prolonged survival when compared with melphalan and prednisone. [2] [3] [4] There is an increasing tendency to offer patients with MM high-dose therapy/stem cell rescue (HDT) as part of the front-line therapy to improve treatment results. In this regard, HDT has proved to be superior to conventional chemotherapy in a randomized trial. 5 Moreover, uncontrolled studies with or without historical control population suggest the superiority of HDT over conventional chemotherapy. [6] [7] [8] [9] While the gold-standard for the evaluation of new treatment strategies is controlled trials, patient accrual into randomized studies is difficult, particularly when a 'conventional' or 'standard' treatment is compared with a new treatment option that creates a higher expectation in both patients and physicians. The purpose of this single institution study was to analyze the outcome of patients with MM who responded to initial chemotherapy and received intensification with HDT/autotransplantation compared to that of those who were continued on standard chemotherapy.
Patients and methods

Inclusion and diagnostic criteria
From 1 January 1990 to 30 June 1998, 64 patients with MM younger than 65 years (median 54, range: 33-64) seen at our institution achieved a response to the initial chemotherapy that lasted for at least 4 months. Because of referral reasons, patients preference or inclusion in trials, 31 of the patients received HDT as early intensification while the remaining 33 were continued on standard chemotherapy.
The diagnosis of MM was established according to the criteria of the Chronic Leukemia-Myeloma Task Force. 10 Patients with asymptomatic myeloma were not included.
Initial chemotherapy
Distribution according to initial chemotherapy is given in Table 1 . The initial treatment consisted of alternating courses of VCMP/VBAP or VBMCP/VBAD in more than 70% of the patients in both arms. 
Criteria of response
Complete response (CR) was defined as: (1) disappearance of the original monoclonal protein in serum and urine by immunofixation, maintained for a minimum of 6 weeks; (2) presence of less than 5% plasma cells in the bone marrow; (3) no increase in size or number of lytic bone lesions; and (4) disappearance of soft tissue plasmacytomas. Partial response required: (1) Ͼ50% reduction in the level of the serum monoclonal protein, maintained for at least 6 weeks; (2) reduction in 24 h urinary light chain protein excretion either by Ͼ90% or to Ͻ200 mg, maintained for a minimum of 6 weeks; (3) Ͼ50% reduction in the size of soft tissue plasmacytomas; and (4) no increase in the size or number of lytic bone lesions. Relapse from CR required at least one of the following: (1) reappearance of serum or urinary paraprotein on immunofixation or routine electrophoresis, confirmed by at least one further investigation and excluding oligoclonal immune reconstitution; (2) Ͼ5% plasma cells on bone marrow aspirate; (3) development of new lytic bone lesions or soft tissue plasmacytomas or definite increase in the size of residual bone lesions; and (4) development of hypercalcemia (corrected serum calcium Ͼ11.5 mg/dl) not attributable to any other cause. Progressive disease (for patients not in CR) required one or more of the following: (1) Ͼ25% increase in the level of serum monoclonal protein, which also had to be an absolute increase of at least 5 g/l confirmed by at least one repeated investigation; (2) Ͼ25% increase in the 24 h urinary light chain protein excretion, which also had to be an absolute increase of at least 200 mg/24 h confirmed by at least one repeated investigation; (3) definite increase in the size of existing bone lesions or soft tissue plasmacytomas; (4) development of new bone lesions or soft tissue plasmacytomas; and (5) development of hypercalcemia (corrected serum calcium Ͼ11.5 mg/dl) not attributable to any other cause.
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Statistical methods
The 2 test was used to assess the statistical significance of multiple comparisons. Overall survival (OS) was calculated from the start of the initial treatment to the date of death or last visit. Event-free survival (EFS) was calculated from the date of initiation of treatment to the date of relapse or disease progression. No patient died while still responding to treatment. Survival curves were plotted according to the method of Kaplan and Meier 12 and statistically compared by means of the log-rank test.
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Results
Comparability of the treatment groups
The pre-treatment characteristics of patients according to the treatment arm are shown in Table 2 . As can be observed, presenting features were similar in both groups, except for median age, which was significantly higher in the subset of patients who continued on the chemotherapy arm.
Response to treatment
Taking into account that criteria for entry into the study were to have achieved at least a partial response, all patients had responded after the initial chemotherapy.
Complete response was achieved in 12 of the 31 (39%) patients intensified with HDT and in two of 33 (6%) of patients who continued on conventional chemotherapy (P = 0.002).
Event-free survival and overall survival
Patients who received intensification with HDT had an EFS significantly longer than those who continued on conventional chemotherapy (median, 43 vs 21 months; P = 0.007) (Figure 1) . However, the OS was not significantly different between groups (median, 62 vs 38 months; P = 0.21) (Figure 2 ). Six patients in the chemotherapy group received HDT as salvage treatment after relapse. Four of them died from progressive disease between 5 and 9 months after Table 2 Initial chemotherapy transplantation, while the remaining two are alive, one in CR and the other in relapse, at 19 and 14 months after the rescue transplant, respectively. Considering only the patients included in the HDT group, patients who achieved CR had significantly longer EFS than did those who achieved a poorer response (median, 51 vs 31 months; P = 0.03) (Figure 3 ). In fact, only four patients who achieved CR have relapsed. Furthermore, the 12 patients who achieved CR with HDT survived significantly longer than the remaining 19 who showed only a partial response (median, not reached vs 50 months; P = 0.006) (Figure 4 ). Of note, all patients who achieved CR are still alive.
The EFS of the 19 patients included in the transplant group who did not achieve CR was not significantly different from the EFS of the overall group of 33 patients who continued on conventional chemotherapy (median, 31 vs 21 months; P = 0.17) ( Figure 5 ). In addition, survival of the patients in the HDT group who remained in PR after transplantation was similar to that of those who continued on conventional chemotherapy (median, 50 vs 38 months; P = 0.63) ( Figure 6 ).
No patients in this series died while in response to treatment and no patient was lost to follow-up.
Discussion
The treatment of MM with conventional chemotherapy is unsatisfactory. The results of a number of trials comparing melphalan and prednisone vs combination chemotherapy, as well as two meta-analysis, concluded that combination chemotherapy does not prolong survival. [1] [2] [3] In addition, the results of two trials comparing conventional chemotherapy at standard doses vs chemotherapy at higher doses found no improvement in survival with the increase in conventional doses. 14, 15 Moreover, the analysis of five population-based Nordic trials has shown no improvement in survival in conventionally treated younger myeloma patients over the last two decades. 4 Considering all of the above, as well as the promising results obtained with high-dose therapy followed by stem cell support, this treatment strategy is increasingly used in patients with newly diagnosed MM in an attempt to improve their long-term outcome.
In a French randomized trial, HDT/bone marrow transplantation improved response rate, EFS and OS when compared with conventional chemotherapy. 5 In contrast, in another randomized trial, recently published in abstract form, HDT was not superior to conventional therapy in patients aged 55 to 65 years. 16 Concerning the latter study, it must be emphasized that the analysis was performed on an intention-to-treat basis and that 25% of the patients allocated to HDT did not receive the planned transplant because of death, complications of chemotherapy, insufficient stem cell collection or patient decision. Thus, the lack of overall benefit in that trial could be due to the fact that a subgroup of older patients did not proceed with autotransplantation, but those who actually received it might have the same advantage as younger patients. There are several multicenter case-control studies in which autotransplantation has been superior to conventional therapy. [6] [7] [8] [9] Nevertheless, the possibility of an unavoidable selection bias in favor of patients entering HDT programmes is of concern. 17, 18 There are three large randomized ongoing trials comparing HDT vs conventional chemotherapy. 19 Hopefully, the results of these trials will help to establish which patients are more likely to benefit from autotransplantation. There are very few data on the results of comparable patients treated with HDT vs conventional chemotherapy at single institutions. In this regard, in a nonrandomized single institution study reported by Alexanian et al, 20 45 patients who received HDT followed by autotransplantation during the first response to chemotherapy had a similar outcome to that of 31 patients, also in first remission, who continued on conventional treatment.
The results of our non-randomized, single institution study show that HDT intensification significantly increased CR and EFS with no significant prolongation in overall survival when compared to continuation of conventional chemotherapy. The lack of significance in overall survival is most likely due to the fact that survival of patients in the chemotherapy arm is similar to that of patients who, in spite of receiving HDT, did not achieve CR. The patients included in the two arms of the present study had similar prognostic features. It is of note, however, that there was a trend towards worse performance status and more anemia in the chemotherapy group. It is likely that with a large number of patients the differences could have reach statistical significance. This potential selection bias in favor of the HDT might, to some degree, account for the better outcome. Although patients included in the HDT arm were significantly younger, this could hardly explain the higher CR rate and the significantly longer EFS observed in this group of patients. Moreover, comparability between both groups is reinforced by the fact that the survival of patients who remained in PR after HDT had a similar outcome to that of those who continued on conventional chemotherapy.
Between 30% and 50% of patients with MM attain CR on stringent criteria (ie negative immunofixation) after HDT. 11 There is growing evidence that the achievement of CR is the crucial fact in the outcome after autologous transplantation. 9, [21] [22] [23] [24] [25] Thus, in the overall experience from the University of Arkansas, 20% of complete responders are projected to remain in response at 7 years. 25 Interestingly, in the subset of 112 patients who achieved CR and who had standard favorable prognostic factors (beta2-M Ͻ2.5 mg/l, CRP Ͻ4 mg/l, and extent of prior standard therapy Ͻ12 months), 55% are projected to be in continued CR at 7 years from the onset of CR. 25 On the other hand, in the MD Anderson experience, 9 the EFS and the overall survival of 22 patients who reached CR were longer than that of the 38 achieving only a PR after HDT. In fact, the EFS of patients achieving PR after transplantation was similar to that of 47 matched-controls who continued on standard therapy. In line with the above results, and in spite of the small number of patients included in our HDT arm, the gain in EFS and overall survival for patients who achieved CR was highly significant. As in the study, by Alexanian et al, 9 there were no significant differences in EFS and OS between patients in PR after HDT and those who continued on conventional therapy. In fact, it is likely that almost all the benefit from HDT comes from patients who attain CR. This highlights the importance of achieving CR. Considering that there is a correlation between the speed and degree of response to the primary chemotherapy treatment and the achievement of CR, 9,26 both choice of initial treatment and timing of HDT are extremely important.
In summary, this non-randomized single institution study shows that early HDT/stem cell intensification increases CR rate and prolongs EFS in patients with MM responding to initial chemotherapy. Furthermore, in the HDT group, patients who achieved CR had an EFS and OS significantly longer than those achieving a lower degree of response. Our results add further evidence to the fact that CR is the first endpoint for a prolonged event-free and overall survival in MM. They also emphasize the importance of strategies to increase CR (ie choice of primary therapy and timing of HDT, selection of high-dose regimen, tandem transplants) 21, 26, 27 and to maintain the remission status (ie interferon, anti-idiotypic vaccination) in patients with MM.
